Expert Opinion - The Undisclosed Risks of Off-brand Ozempic and Other Weight Loss Products

Oct 11, 2024

4 min

C. Michael  White, Pharm.D., FCP, FCCP

The popularity -- and price -- of brand-name injectable drugs like Ozempic, Wegovy, Mounjaro, and Zepbound has skyrocketed.


But the soaring demand for these drugs -- used for weight loss as well as to control blood sugar levels and reduce the risk of heart disease -- and the limited supply as well as lack of generic options has also led to a flood of non-brand alternatives in the market.


In a recent article for The Conversation, UConn expert C. Michael White, Distinguished Professor of Pharmacy Practice, issued a warning to consumers about the potential undisclosed risks of these off-brand products:



High demand is driving GLP-1 wannabes

The dietary supplement market has sought to cash in on the GLP-1 demand with pills, teas, extracts and all manner of other products that claim to produce similar effects as the brand names at a much lower price.

Products containing the herb berberine offer only a few pounds of weight loss, while many dietary supplement weight loss products contain stimulants such as sibutramine and laxatives such as phenolphthalein, which increase the risk of heart attacks, strokes and cancer.




The role of compounding pharmacies

Unlike the dietary supplements that are masquerading as GLP-1 weight loss products, compounding pharmacies can create custom versions of products that contain the same active ingredients as the real thing for patients who cannot use either brand or generic products for some reason.

These pharmacies can also produce alternative versions of brand-name drugs when official drug shortages exist.

Since the demand for GLP-1 medications has far outpaced the supply, compounding pharmacies are legally producing a variety of different semaglutide and tirzepatide products.

These products may come in versions that differ from the brand-name companies, such as vials of powder that must be dissolved in liquid, or as tablets or nasal sprays.

Just like the brand-name drugs, you must have a valid prescription to receive them. The prices range from $250-$400 a month – still a steep price for many consumers.

Compounding pharmacies must adhere to the FDA’s sterility and quality production methods, but these rules are not as rigorous for compounding pharmacies as those for commercial manufacturers of generic drugs.

In addition, the products compounding pharmacies create do not have to be tested in humans for safety or effectiveness like brand-name products do.

Proper dosing can also be challenging with compounded forms of the drugs.

Companies that work the system

For people who cannot afford a compounding pharmacy product, or cannot get a valid prescription for semaglutide or tirzepatide, opportunistic companies are stepping in to fill the void. These include “peptide companies,” manufacturers that create non-FDA approved knockoff versions of the drugs.

From November 2023 to March 2024, my team carried out a study to assess which of these peptide companies are selling semaglutide or tirzepatide products. We scoured the internet looking for these peptide companies and collected information about what they were selling and their sales practices.

We found that peptide sellers use a loophole to sell these drugs. On their websites, the companies state that their drugs are for “research purposes only” or “not for human consumption,” but they do nothing to verify that the buyers are researchers or that the product is going to a research facility.

By reading the comments sections of the company websites and the targeted ads on social media, it becomes clear that both buyers and sellers understand the charade. Unlike compounding pharmacies, these peptide sellers do not provide the supplies you need to dissolve and inject the drug, provide no instructions, and will usually not answer questions.

Peptide sellers, since they allegedly are not selling to consumers, do not require a valid prescription and will sell consumers whatever quantity of drug they wish to purchase. Even if a person has an eating disorder such as anorexia nervosa, the companies will happily sell them a semaglutide or tirzepatide product without a prescription. The average prices of these peptide products range from $181-$203 per month.



Skirting regulations

Peptide sellers do not have to adhere to the rules or regulations that drug manufacturers or compounding pharmacies do. Many companies state that their products are 99% pure, but an independent investigation of three companies’ products from August 2023 to March 2024 found that the purity of the products were far less than promised.

One product contained endotoxin – a toxic substance produced by bacteria – suggesting that it was contaminated with microbes. In addition, the products’ promised dosages were off by up 29% to 39%. Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

In this study, some companies never even shipped the drug, telling the buyers they needed to pay an additional fee to have the product clear customs.

If a consumer is harmed by a poor-quality product, it would be difficult to sue the seller, since the products specifically say they are “not for human consumption.” Ultimately, consumers are being led to spend money on products that may never arrive, could cause an infection, might not have the correct dose, and contain no instructions on how to safely use or store the product.



Dr. C. Michael White is an expert in the areas of comparative effectiveness and preventing adverse events from drugs, devices, dietary supplements, and illicit substances.


Dr. White is available to speak with media -- click on his icon now to arrange an interview today.




Connect with:
C. Michael  White, Pharm.D., FCP, FCCP

C. Michael White, Pharm.D., FCP, FCCP

Head and Distinguished Professor, Department of Pharmacy Practice

Dr. White’s research interests are in drug, dietary supplement, and illicit drug safety, quality, and cost

DietCBDDrug CostsDietary SupplementsCardiovascular Drugs
Powered by

You might also like...

Check out some other posts from University of Connecticut

Can Nature Adapt Fast Enough? Mark Urban Explores Whether Ecosystems Can Evolve With Climate Change featured image

3 min

Can Nature Adapt Fast Enough? Mark Urban Explores Whether Ecosystems Can Evolve With Climate Change

As scientists investigate whether an entire Arctic ecosystem can evolve in response to a rapidly warming climate, UConn’s Mark Urban brings leading expertise on the intersection of evolution, biodiversity, and climate change. Climate change is transforming the Arctic faster than almost anywhere else on Earth. Earlier snowmelt, warmer temperatures, and changing waterways are altering habitats and putting new pressures on the plants and animals that depend on them. But what if nature can evolve in response, not simply one species at a time, but as an interconnected ecosystem? That is the ambitious question behind a six-year, $15-million National Science Foundation-funded research project recently featured in The Guardian. Scientists working on Alaska’s North Slope are studying five interconnected species — white-crowned sparrows, feltleaf willow, Arctic grayling, aquatic mayflies, and ground beetles — to understand whether ecological relationships themselves can evolve as the climate changes. It is a question that sits squarely within the expertise of Mark C. Urban, Ph.D., Professor and Arden Chair of Ecology and Evolutionary Biology at the University of Connecticut. Urban is a global expert on the impact of climate change on biodiversity, eco-evolution, and extinction risk. His research integrates ecology, evolution, and genetics to better understand how species and ecological communities respond to environmental change. He has also conducted extensive field research in Alaska, including research involving Arctic grayling and their ability to respond to a rapidly changing climate. Recently, his work was featured in an in-depth piece by The Guardian. “Across hundreds of experiments, we have seen this happening,” says Mark Urban, an evolutionary biologist at the University of Connecticut working on the project. “There is this incredible buffer ability of adaptive evolution.” How the evolution of one species can help the holistic ecosystems depends on how an adaptive trait ultimately translates into ecological properties. For example, if a fish species can quickly evolve, it means that not only is the population maintained, but so is the stream’s productivity. “Any ecological properties that depend on those populations are maintained as well,” Urban says. To get a better idea of whether the Arctic’s stream and tundra habitats will continue to prosper, scientists are mapping the genetic diversity of each of the five study species to see if there is enough to allow for adaptation – influencing the ecosystems’ resilience potential. “We can get so far with ecology, but at some point we want to get down to the basics of why organisms do the things they do, and can they change the things they do,” says Urban. “That’s something only genetics can explain.” Certain genes control the traits associated with succeeding in different environments. “The holy grail in genomics is to find that one gene that affects everything. The gene that rules them all,” he says. “I think that’s optimistic. Most of the traits are going to be determined by hundreds of thousands of genes.”  The Guardian - September 2026 Studies reveal that many plants and animals have been able to persist through evolutionary rescue – the process by which a population on the brink of extinction survives and rebounds through rapid genetic adaptation. Scarlet monkeyflowers in Oregon and California, for example, rapidly evolved during the 2010s to survive a four-year drought. The implications extend far beyond the Arctic. Scientists have traditionally examined how individual species might migrate, acclimatize, or evolve as their environments change. But ecosystems are networks. Fish depend on insects, insects depend on vegetation and water conditions, and predators depend on prey. If those relationships change at different speeds, the consequences can ripple throughout an ecosystem. Urban's work examines precisely these kinds of connections — how ecological and evolutionary processes interact and ultimately influence biodiversity and the resilience of natural systems. His recent research has also examined the growing risk of species extinction as global temperatures rise. The emerging science raises some fascinating questions: How quickly can evolution occur? Can genetic diversity give ecosystems a natural buffer against climate change? What happens when one species adapts faster than another? And are there limits to how much change an ecosystem can absorb before it begins to unravel? As scientists attempt to understand whether nature can keep pace with a rapidly changing planet, Urban can provide valuable perspective on what evolution can — and cannot — do, and what the findings could mean for biodiversity and conservation around the world. If you're interested in speaking with Mark Urban about climate change, evolution, biodiversity, Arctic ecosystems, or extinction risk, click on his profile below.

Expert Opinion: DIY Peptide Injections Carry Risks Most People Never See Coming featured image

3 min

Expert Opinion: DIY Peptide Injections Carry Risks Most People Never See Coming

Peptides are having a moment. People injecting them at home are chasing everything from weight loss and muscle recovery to sharper thinking and better sex drive. But according to UConn pharmacist and clinical pharmacologist C. Michael White, the bigger danger isn't just what's in the vial. It's what happens when untrained people try to draw up and inject these products themselves. White has been researching the gray markets for peptides, where companies sidestep FDA oversight by selling products labeled "for research purposes only." Because that labeling is a legal workaround, the companies can't legally tell buyers how to actually use what they're selling. "This means consumers must purchase any supplies they need and figure out the proper technique on their own," White writes. So he decided to test just how well people manage on their own. In a new study published in Public Health Reports, White and his colleagues recruited 20 people, 10 college students and 10 adults in their 60s, and asked each to reconstitute a semaglutide peptide product, draw it into a syringe, and inject a mannequin. They were allowed to research the process online or with AI beforehand. The results were rough. On average, both age groups got fewer than half the steps right. Some picked expired or cloudy dissolving liquid. Many miscalculated doses, couldn't clear air bubbles from the syringe, or injected into muscle instead of fat. Roughly half didn't know how to safely engage the needle's safety mechanism or dispose of it afterward. "These errors were serious and could increase the risk of infection, bleeding, over- or under-dosing, and needle sticks," White notes. What stood out most: Confidence didn't track with competence. After doing their homework, most participants in both groups felt "somewhat confident" they could do the injection correctly. Younger participants stayed confident even after fumbling through the process. Older adults, by contrast, adjusted their confidence downward once they saw how it actually went, which tracks with prior research showing older adults tend to be more accurate judges of their own ability on complex tasks. White's piece also digs into a potential fix on the table: In late July 2026, an FDA advisory panel recommended adding six widely used peptides, including BPC-157, TB-500, and Semax, to the list of substances compounding pharmacies can legally prepare. The panel's argument is that compounded versions would be safer than gray-market ones, since compounding pharmacies follow rules on sourcing and sterile production that the gray market doesn't. White isn't fully sold. Even if the FDA adopts the recommendation, he points out it would only apply to a handful of products, and it wouldn't change the fact that none of them have actually been tested for safety or effectiveness as finished drugs. The bulk of the gray-market risk stays exactly where it is. For more on the peptide boom and what the FDA is weighing, NBC News broke down the basics here: What are peptides and why is the FDA considering easing limits? Read the full article: Dr. White is Head and Distinguished Professor of the Department of Pharmacy Practice at the University of Connecticut, and co-director of the university's Health Outcomes, Policy, and Evidence Synthesis (HOPES) research group. His research focuses on drug, dietary supplement, and illicit drug safety, quality, and cost, with a specific throughline into adverse events tied to drugs, devices, herbal products, and substances of abuse. View complete profile He's a recurring voice on drug and supplement safety specifically, most recently quoted in Health magazine's "4 Major Risks of Unregulated Peptides" (Aug. 18, 2026) and on KCBS Los Angeles radio discussing GLP-1 drugs and youth mental health (Aug. 10, 2026). Dr. White is available for interviews on peptide safety, the gray-market supplement industry, GLP-1 and weight-loss drug trends, and drug/dietary supplement safety more broadly. Media can reach out by clicking this profile icon below.

UConn Expert Weighs In on FIFA's Hottest New Timeout featured image

3 min

UConn Expert Weighs In on FIFA's Hottest New Timeout

For the first time in FIFA World Cup history, every match at the 2026 tournament includes mandatory three-minute hydration breaks midway through each half. Introduced as a player welfare measure amid concerns about extreme summer temperatures across North America, the breaks have quickly become a much discussed development in the tournament. Coaches, players, broadcasters, sports scientists, and fans are all weighing in on the impact the stoppages have on player safety, game flow, strategy, and even commercial opportunities. The conversation has intensified as several matches have been played in challenging heat conditions and prominent coaches have publicly questioned whether the mandatory breaks alter the rhythm of the sport. At the same time, medical experts continue to emphasize the risks posed by heat stress and dehydration during elite athletic competition, particularly in tournaments spanning multiple climates and venues. Experts like UConn's Douglas Casa have been front and center when the media call for insight and perspective. The three-minute mandatory hydration breaks are meant to protect players, and referees, from extreme heat illness and help them maintain their physical performance. In that time, players can cool off and replenish lost water and salt from sweating, but how effective it is depends on how aggressive the cooling methods are. That could mean putting wet, cold towels on the exposed parts of a player's body, such as the neck, head, back and arms. If done well, that could reduce their body temperature by about 0.22 F (0.12 C) per minute, said Douglas Casa, CEO of the University of Connecticut's Korey Stringer Institute who also co-signed the letter to FIFA. "Some people can tolerate a little more fluids comfortably and then do intense exercise. Some people can't because it sloshes around in their stomach and they don't feel super comfortable, so they might not drink as much in such a short period of time," he added. The time, he said, dictates the volume of impact, whether from fluid or cooling, and "that's why we're suggesting doing something like five or six minutes, because it just makes such a big impact when you're dealing with a change of that magnitude." June 18 - NPR Douglas Casa is a professor of kinesiology and chief executive officer of UConn’s Korey Stringer Institute. He is a leading authority on research, advocacy, and education about exertional heat stroke View his profile While the standardized breaks represent a major step forward for player welfare, some leading heat illness experts argue the new policy does not go far enough. Dr. Douglas Casa, a professor of kinesiology at the University of Connecticut and chief executive officer of the Korey Stringer Institute, expressed skepticism regarding the efficacy of such brief intervals. Dr. Casa warned that prolonged, high-intensity physical exertion causes a rapid spike in core body temperature, which dramatically degrades athletic performance and increases the risk of exertional heat illness. He noted that a mere three minutes from whistle to whistle provides insufficient time for optimal physiological cooling and active rehydration, recommending instead that tournament officials expand the mandatory breaks to five or six minutes. Faced with these demanding environmental conditions, several competing national teams are taking proactive measures to gain a competitive edge. Multiple countries have expanded their technical staffs to include specialized sports scientists tasked exclusively with designing aggressive heat-acclimatization and thermal-management strategies. According to Dr. Casa, these data-driven preparation strategies will likely play a monumental role in determining player durability and ultimately crowning the world champion. June 09 - NBC News Covering? We can help. Douglas Casa, who leads UConn's renowned Korey Stringer Institute, is available to discuss: The science behind hydration and cooling breaks in elite sport Heat illness risks facing World Cup athletes Whether mandatory breaks are sufficient to protect players How extreme weather is changing sports medicine and event management The balance between player safety, competition, and fan expectations Check out the video below featuring Doug Casa explaining what happens when the human body gets too hot. Media interested in speaking with Doug Casa can contact the UConn media relations team to arrange an interview.

View all posts